Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

X4 Pharmaceuticals Inc (XFOR)

X4 Pharmaceuticals Inc (XFOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

X4 Pharmaceuticals Inc 61 North Beacon Street 4th Floor Boston MA 02134 USA

www.x4pharma.com Employees: 45 P: 857-529-8300

Sector:

Medical

Description:

X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States.

Key Statistics

Overview:

Market Capitalization, $K 362,771
Enterprise Value, $K 222,011
Shares Outstanding, K 90,920
Float, K 89,893
% Float 98.87%
Short Interest, K 3,498
Short Float 3.85%
Days to Cover 5.65
Short Volume Ratio 0.38
% of Insider Shareholders 1.13%
% of Institutional Shareholders 72.03%

Financials:

Annual Sales, $ 35,110 K
Annual Net Income, $ -79,200 K
Last Quarter Sales, $ 2,570 K
Last Quarter Net Income, $ -23,930 K
EBIT, $ -86,880 K
EBITDA, $ -85,600 K

Growth:

1-Year Return -44.93%
3-Year Return -83.31%
5-Year Return -98.47%
5-Year Revenue Growth 1,070.33%
5-Year Earnings Growth 97.98%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.22 on 03/17/26
Next Earnings Date 05/07/26
Earnings Per Share ttm -4.34
EPS Growth vs. Prev Qtr 68.12%
EPS Growth vs. Prev Year 96.34%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-30 on 04/28/25

XFOR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -115.27%
Return-on-Assets % -45.97%
Profit Margin % -225.58%
Debt/Equity 0.41
Price/Sales 10.46
Price/Cash Flow N/A
Price/Book 1.90
Book Value/Share 2.13
Interest Coverage -7.91
60-Month Beta 0.43
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.